Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer

Abstract Background Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV) was approved for unresectable pancreatic cancer (UR-PC) in March 2020 in Japan. Levo-LV is administered by intravenous infusion over 120 min following 90 min intravenous infusion of nal-IRI (c...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ryoji Takada, Kenji Ikezawa, Takuo Yamai, Ko Watsuji, Yusuke Seiki, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Makiko Urabe, Yugo Kai, Tasuku Nakabori, Hiroyuki Uehara, Michiyo Kotani, Toshinari Yagi, Miho Kimura, Keisuke Nozaki, Mari Takagi, Kazuyoshi Ohkawa
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2023-07-01
Saila:	BMC Cancer
Gaiak:	Pancreatic cancer Nanoliposomal irinotecan Levo-leucovorin Chemotherapy
Sarrera elektronikoa:	https://doi.org/10.1186/s12885-023-11205-6
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!